ABVC BioPharma Receives Taiwanese Patent for Major Depressive Disorder Treatment

ABVC BioPharma, a clinical-stage biopharmaceutical company specializing in therapeutic solutions for ophthalmology, neurology, and oncology/hematology, has announced the acquisition of a Taiwanese patent for the use of PDC-1421, a Radix Polygala extract, in the treatment of Major Depressive Disorder (MDD). This comes after the company was granted a US patent for the same treatment earlier this year.

The Taiwanese patent, Application No. 109130285, provides ABVC BioPharma with exclusive rights to utilize, offer, and sell PDC-1421 in Taiwan until 2040. Dr. Uttam Patil, the Chief Executive Officer of ABVC, expressed excitement about the global coverage of their patent map and the pending applications in the European Union, China, Japan, and other regions.

The patent application, titled “Polygala Extract for the Treatment of Major Depressive Disorder,” focuses on the oral administration of a capsule containing PDC-1421 for MDD treatment. The recommended administration period is at least 25 days, with daily doses ranging from 380-760 mg of the botanical extraction.

ABV-1504, the company’s asset indicated for use in MDD, is a botanical-based Norepinephrine Transporter (NET) inhibitor that has successfully completed Phase II clinical studies. ABVC BioPharma plans to initiate an End of Phase II (EOP II) meeting with the FDA to further advance the development of this treatment.

The market potential for MDD treatments is significant, with the MDD market projected to reach $14.96 billion by 2032, according to a report by Future Market Insights. Additionally, the global ADHD treatment market, in which ABVC BioPharma is also involved, is expected to reach $32.14 billion by 2030, as stated in a report by Polaris Market Research.

ABVC BioPharma is a clinical-stage biopharmaceutical company with a robust pipeline of six drugs and one medical device under development. The company collaborates with renowned research institutions such as Stanford University, the University of California at San Francisco, and Cedars-Sinai Medical Center.

For media inquiries, please contact Tom Masterson at tmasterson@allelecomms.com.